9.2 PROTOCOL SPECIFIC RESEARCH SUPPORT The goal of Protocol-Specific Research is to provide research nursing and data management support for conducting and completing innovative, early feasibility or proof-of-principle clinical trials originating from Arizona Cancer Center Programs. Priorities to obtain funding through this core will be given to translational clinical research studies. These may emanate from basic research at the Arizona Cancer Center, or they may involve laboratory correlates with concepts developed by clinicians. In either case, the top priority will be given to Investigator Initiated Trials (IITs). The University of Arizona continues to support the growth of the Investigator Initiated and early Phase I research studies, as demonstrated by an additional allocation of $500,000 in the current year for our clinical research efforts overall, and very specifically the innovative and early phase clinical studies. Minimum criteria for access to AZCC Protocol-Specific Research funds include the following: ? Research hypothesis was generated by an AZCC clinical investigator; ? Clinical trial represents a new initiative; ? Clinical trial has received approval with high priority from the AZCC Scientific Review Committee and the University of Arizona Human Subject's Committee; ? Principal investigator is a member of the AZCC; ? Final approval and disposition of these funds will be made by the AZCC Resource Committee. The Arizona Cancer Center Resource Allocation Committee meets bi-monthly and is composed of clinical investigators in leadership positions in AZCC Programs and Administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-32
Application #
8077351
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
32
Fiscal Year
2010
Total Cost
$97,439
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Hsu, Chiu-Hsieh; Yu, Mandi (2018) Cox regression analysis with missing covariates via nonparametric multiple imputation. Stat Methods Med Res :962280218772592
Agasid, Mark T; Wang, Xuemin; Huang, Yiding et al. (2018) Expression, purification, and electrophysiological characterization of a recombinant, fluorescent Kir6.2 in mammalian cells. Protein Expr Purif 146:61-68
Wales, Jessica A; Chen, Cheng-Yu; Breci, Linda et al. (2018) Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase. J Biol Chem 293:1850-1864
Bell, Melanie L (2018) New guidance to improve sample size calculations for trials: eliciting the target difference. Trials 19:605
Lindeman, Leila R; Randtke, Edward A; High, Rachel A et al. (2018) A comparison of exogenous and endogenous CEST MRI methods for evaluating in vivo pH. Magn Reson Med 79:2766-2772
Remeniuk, Bethany; King, Tamara; Sukhtankar, Devki et al. (2018) Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain 159:684-698
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli et al. (2018) The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog 57:182-192
Russ, Atlantis; Hua, Anh B; Montfort, William R et al. (2018) Blocking ""don't eat me"" signal of CD47-SIRP? in hematological malignancies, an in-depth review. Blood Rev 32:480-489

Showing the most recent 10 out of 1336 publications